Induction of muscle weakness by local inflammation: An experimental animal model

Inflammation Research

Volumn 58, Issue 4, 2009, Pages 175-183

  Bicer, S ^a   Reiser, P J ^a   Ching, S ^a   Quan, N ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Force; Isoform; Myosin heavy chain; Skeletal muscle

Indexed keywords

CASEIN; MYOSIN HEAVY CHAIN; SODIUM CHLORIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CONTROLLED STUDY; ELECTROPHORESIS; EXPERIMENTAL MODEL; FORCE; HINDLIMB; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTION; ISOMETRICS; LEUKOCYTE; MACROPHAGE; MOUSE; MUSCLE FUNCTION; MUSCLE LEVEL; MUSCLE TETANIC CONTRACTION; MUSCLE TWITCH; MUSCLE WEAKNESS; NEUTROPHIL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SOLEUS MUSCLE;

ANIMALS; CASEINS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSIN HEAVY CHAINS;

EID: 62949106761     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-008-8093-7     Document Type: Article

References (49)

1. Verleye M, Heulard I, Stephens JR, Levy RH, Gillardin JM. Effects of citrulline malate on bacterial lipopolysaccharide induced endotoxemia in rats. Arzneimittelforschung 1995; 45: 712-5.
2. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int J Cardiol 2002; 85: 89-99.
3. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006; 42: 31-41.
4. Coats AJ. Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. Int J Cardiol 2002; 85: 133-9.
5. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002; 85:161-71.
6. Bellomo R. The cytokine network in the critically ill. Anaesth Intensive Care 1992; 20: 288-302.
7. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98: 911-7.
8. Winkelman C. Inactivity and inflammation: selected cytokines as biologic mediators in muscle dysfunction during critical illness. AACN Clin Issues 2004; 15: 74-82.
9. Podell M. Inflammatory myopathies. Vet Clin North Am Small Anim Pract 2002; 32: 147-67.
10. Rouger K, Louboutin JP, Villanova M, Cherel Y, Fardeau M. X-linked vacuolated myopathy: TNF-alpha and IFN-gamma expression in muscle fibers with MHC class I on sarcolemma. Am J Pathol 2001; 158: 355-9.
11. Son K, Tomita Y, Shimizu T, Nishinarita S, Sawada S, Horie T. Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. Intern Med 2000; 39: 128-35.
12. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 2004; 43: 524-6.
13. Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003; 6: 295-9.
14. Girten B, McPherson S, Lee M, Grethe N, McDowell R, McPherson L, et al. Effectiveness of a cytokine restraining agent (CRA (TM)) in attenuating disuse deconditioning induced by hindlimb unloading in rats. J Gravit Physiol 1995; 2: P121-2.
15. Bennett R. Fibromyalgia: present to future. Curr Rheumatol Rep 2005; 7: 371-6.
16. Lang CH, Fan J, Cooney R, Vary TC. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol 1996; 270: E430-7.
17. de Groof F, Joosten KF, Janssen JA, de Kleijn ED, Hazelzet JA, Hop WC, et al. Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J Clin Endocrinol Metab 2002; 87: 3118-24.
18. Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN. Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am J Physiol Endocrinol Metab 2002; 283: E472-81.
19. Lang CH, Krawiec BJ, Huber D, McCoy JM, Frost RA. Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2006; 290: R963-72.
20. Haden ST, Glowacki J, Hurwitz S, Rosen C, LeBoff MS. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int 2000; 66: 414-8.
21. Street ME, de'Angelis G, Camacho-Hubner C, Giovannelli G, Ziveri MA, Bacchini PL, et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res 2004; 61: 159-64.
22. Lee SD, Huang CY, Shu WT, Chen TH, Lin JA, Hsu HH, et al. Proinflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. Clin Chim Acta 2006.
23. Szewczyk NJ, Jacobson LA. Signal-transduction networks and the regulation of muscle protein degradation. Int J Biochem Cell Biol 2005; 37: 1997-2011.
24. Mealy K, van Lanschot JJ, Robinson BG, Rounds J, Wilmore DW. Are the catabolic effects of tumor necrosis factor mediated by glucocorticoids? Arch Surg 1990; 125: 42-7; discussion 47-8.
25. Colson A, Willems B, Thissen JP. Inhibition of TNF-alpha production by pentoxifylline does not prevent endotoxin-induced decrease in serum IGF-I. J Endocrinol 2003; 178: 101-9.
26. Fernandez-Celemin L, Pasko N, Blomart V, Thissen JP. Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 2002; 283: E1279-90.
27. Kaminski NE, Holsapple MP. A functional characterization of macrophage alterations in casein-treated B6C3F1 mice. Immunopharmacology 1992; 24: 229-40.
28. Kitamura M, Goto F, Ohkawara S, Yoshinaga M. Production of pyrogen by polymorphonuclear leukocytes during the course of casein-induced peritonitis in rabbits. Acta Pathol Jpn 1986; 36: 791-803.
29. Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005; 146: 4887-97.
30. Bicer S, Reiser PJ. Myosin light chain isoform expression among single mammalian skeletal muscle fibers: species variations. J Muscle Res Cell Motil 2004; 25: 623-33.
31. Bicer S, Reiser PJ. Variations in apparent mass of mammalian fasttype myosin light chains correlate with species body size, from shrew to elephant. Am J Physiol Regul Integr Comp Physiol 2007; 292: R527-34.
32. Bergrin M, Bicer S, Lucas CA, Reiser PJ. Three-dimensional compartmentalization of myosin heavy chain and myosin light chain isoforms in dog thyroarytenoid muscle. Am J Physiol Cell Physiol 2006; 290: C1446-58.
33. Pizza FX, Peterson JM, Baas JH, Koh TJ. Neutrophils contribute to muscle injury and impair its resolution after lengthening contractions in mice. J Physiol 2005; 562: 899-913.
34. Falasca GF, Reginato AJ. The spectrum of myositis and rhabdomyolysis associated with bacterial infection. J Rheumatol 1994; 21: 1932-7.
35. Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 2006; 80: 737-49.
36. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006; 66: S33-8.
37. Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pecheux C, Testard H, et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59: 905-11.
38. Maldonado IR, Ferreira ML, Camargos ER, Chiari E, Machado CR. Skeletal muscle regeneration and Trypanosoma cruzi-induced myositis in rats. Histol Histopathol 2004; 19: 85-93.
39. Michael JR, Mitch WE. Reversible renal failure and myositis caused by phenytoin hypersensitivity. Jama 1976; 236: 2773-5.
40. Quan N, Herkenham M. Connecting cytokines and brain: a review of current issues. Histol Histopathol 2002; 17: 273-88.
41. Jennische E. Ischaemia-induced injury in glycogen-depleted skeletal muscle. Selective vulnerability of FG-fibres. Acta Physiol Scand 1985; 125: 727-34.
42. Lieber RL, Friden J. Selective damage of fast glycolytic muscle fibres with eccentric contraction of the rabbit tibialis anterior. Acta Physiol Scand 1988; 133: 587-8.
43. Fernandez-Sola J, Sacanella E, Estruch R, Nicolas JM, Grau JM, Urbano-Marquez A. Significance of type II fiber atrophy in chronic alcoholic myopathy. J Neurol Sci 1995; 130: 69-76.
44. d'Albis A, Couteaux R, Janmot C, Roulet A, Mira JC. Regeneration after cardiotoxin injury of innervated and denervated slow and fast muscles of mammals. Myosin isoform analysis. Eur J Biochem 1988; 174: 103-10.
45. d'Albis A, Couteaux R, Janmot C, Mira JC. Myosin isoform transitions in regeneration of fast and slow muscles during postnatal development of the rat. Dev Biol 1989; 135: 320-5.
46. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003; 60: 569-80.
47. Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003; 24: 155-8.
48. Lopez-Alemany R, Suelves M, Munoz-Canoves P. Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis. Thromb Haemost 2003; 90: 724-33.
49. Sun H, Liu J, Ding F, Wang X, Liu M, Gu X. Investigation of differentially expressed proteins in rat gastrocnemius muscle during denervation-reinnervation. J Muscle Res Cell Motil 2006; 27: 241-50.